Category: Lecanemab
-
“LEQEMBI” Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Israel By Investing.com
•
TOKYO and CAMBRIDGE, Mass., July 12, 2024 – (JCN NewsWire) – Eisai Co., Ltd. (OTC:) and Biogen Co., Ltd. (NASDAQ:) today announced the approval of the beta-amyloid (Aβ)-degrading monoclonal antibody “LEQEMBI” (generic name: lecanemab) in Israel as a treatment for Alzheimer’s disease (AD). Treatment with LEQEMBI should be initiated in…